Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCG vaccine F-70
- Development stage
- Unknown
- Lead developer
- Institute of Infectious and Parasitic Diseases
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
BCG vaccine F-70 is a subcellular fraction derived from the Bacillus Calmette-Guérin (BCG) Sofia strain (SL222). Unlike traditional live-attenuated BCG vaccines, F-70 is a water-soluble, non-viable preparation containing cellular components of the mycobacteria. It was developed in Bulgaria for use as a non-specific immunotherapeutic agent. In clinical practice, particularly during the late 20th century, it was administered intradermally to patients with superficial bladder cancer to stimulate the systemic immune system, often in conjunction with intravesical instillations of live BCG (such as Calgevax). The preparation aims to induce a robust cellular immune response, activating macrophages and T-lymphocytes to recognize and eliminate malignant cells.
- Other names
- F-70 subcellular preparationF70 subcellular preparationF 70 subcellular preparationF-70 BCG fractionF70 BCG fractionF 70 BCG fractionF-70 subcellular fractionF70 subcellular fractionF 70 subcellular fraction
02
Targets
TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on BCG vaccine F-70.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCG vaccine F-70.